Literature DB >> 32976909

Structural Insights into N-terminal IgV Domain of BTNL2, a T Cell Inhibitory Molecule, Suggests a Non-canonical Binding Interface for Its Putative Receptors.

Aditya J Basak1, Snigdha Maiti1, Anita Hansda2, Dhrubajyoti Mahata3, Kheerthana Duraivelan1, Shankar V Kundapura4, Woonghee Lee5, Gayatri Mukherjee6, Soumya De7, Dibyendu Samanta8.   

Abstract

T cell costimulation is mediated by the interaction of a number of receptors and ligands present on the surface of the T cell and antigen-presenting cell, respectively. Stimulatory or inhibitory signals from these receptor-ligand interactions work in tandem to preserve immune homeostasis. BTNL2 is a type-1 membrane protein that provides inhibitory signal to T cells and plays an important role in several inflammatory and autoimmune diseases. Therefore, manipulation of the molecular interaction of BTNL2 with its putative receptor could provide strategies to restore immune homeostasis in these diseases. Hence, it is imperative to study the structural characteristics of this molecule, which will provide important insights into its function as well. In this study, the membrane-distal ectodomain of murine BTNL2 was expressed in bacteria as inclusion bodies, refolded in vitro and purified for functional and structural characterization. The domain is monomeric in solution as demonstrated by size-exclusion chromatography and analytical ultracentrifugation, and also binds to its putative receptor on naïve B cells and activated T cell subsets. Importantly, for the first time, we report the structure of BTNL2 as determined by solution NMR spectroscopy and also the picosecond-nanosecond timescale backbone dynamics of this domain. The N-terminal ectodomain of BTNL2, which was able to inhibit T cell function as well, exhibits distinctive structural features. The N-terminal ectodomain of BTNL2 has a significantly reduced surface area in the front sheet due to the non-canonical conformation of the CC' loop, which provides important insights into the recognition of its presently unknown binding partner.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  T cell costimulation; butyrophilins; determination of protein structure by NMR spectroscopy; immunoglobulin fold; immunoglobulin-variable domain

Mesh:

Substances:

Year:  2020        PMID: 32976909      PMCID: PMC7642044          DOI: 10.1016/j.jmb.2020.09.013

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  47 in total

1.  Expression, refolding, purification, molecular characterization, crystallization, and preliminary X-ray analysis of the receptor binding domain of human B7-2.

Authors:  Xuewu Zhang; Jean-Claude D Schwartz; Steven C Almo; Stanley G Nathenson
Journal:  Protein Expr Purif       Date:  2002-06       Impact factor: 1.650

2.  Direct detection of CH/pi interactions in proteins.

Authors:  Michael J Plevin; David L Bryce; Jérôme Boisbouvier
Journal:  Nat Chem       Date:  2010-05-02       Impact factor: 24.427

3.  BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation.

Authors:  Thang Nguyen; Xikui K Liu; Yongliang Zhang; Chen Dong
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

4.  Identification of helix capping and b-turn motifs from NMR chemical shifts.

Authors:  Yang Shen; Ad Bax
Journal:  J Biomol NMR       Date:  2012-03       Impact factor: 2.835

Review 5.  The immunoglobulin fold. Structural classification, sequence patterns and common core.

Authors:  P Bork; L Holm; C Sander
Journal:  J Mol Biol       Date:  1994-09-30       Impact factor: 5.469

6.  Sarcoidosis is associated with a truncating splice site mutation in BTNL2.

Authors:  Ruta Valentonyte; Jochen Hampe; Klaus Huse; Philip Rosenstiel; Mario Albrecht; Annette Stenzel; Marion Nagy; Karoline I Gaede; Andre Franke; Robert Haesler; Andreas Koch; Thomas Lengauer; Dirk Seegert; Norbert Reiling; Stefan Ehlers; Eberhard Schwinger; Matthias Platzer; Michael Krawczak; Joachim Müller-Quernheim; Manfred Schürmann; Stefan Schreiber
Journal:  Nat Genet       Date:  2005-02-27       Impact factor: 38.330

7.  BTN3A1 Discriminates γδ T Cell Phosphoantigens from Nonantigenic Small Molecules via a Conformational Sensor in Its B30.2 Domain.

Authors:  Mahboob Salim; Timothy J Knowles; Alfie T Baker; Martin S Davey; Mark Jeeves; Pooja Sridhar; John Wilkie; Carrie R Willcox; Hachemi Kadri; Taher E Taher; Pierre Vantourout; Adrian Hayday; Youcef Mehellou; Fiyaz Mohammed; Benjamin E Willcox
Journal:  ACS Chem Biol       Date:  2017-09-14       Impact factor: 5.100

8.  Association of genetic polymorphisms on BTNL2 with susceptibility to and prognosis of dilated cardiomyopathy in a Chinese population.

Authors:  Liang Cheng; Rong Zhao; ZhenXiao Jin; Kai Ren; Chao Deng; Shiqiang Yu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

9.  In vivo administration of recombinant BTNL2-Fc fusion protein ameliorates graft-versus-host disease in mice.

Authors:  Cheng Cui; Xiaohong Tian; Yujun Lin; Min Su; Qingquan Chen; Shao-Yuan Wang; Laijun Lai
Journal:  Cell Immunol       Date:  2018-10-26       Impact factor: 4.868

10.  A centrifugation-based physicochemical characterization method for the interaction between proteins and nanoparticles.

Authors:  Ahmet Bekdemir; Francesco Stellacci
Journal:  Nat Commun       Date:  2016-10-20       Impact factor: 14.919

View more
  1 in total

1.  Experimental Study of Potential CD8+ Trivalent Synthetic Peptides for Liver Cancer Vaccine Development Using Sprague Dawley Rat Models.

Authors:  Sidra Zafar; Baogang Bai; Jinlei Guo; Syed Aun Muhammad; Syeda Tahira Qousain Naqvi; Muhammad Nauman Shabbir; Imran Imran; Rehan Sadiq Shaikh; Amjad Ali
Journal:  Biomed Res Int       Date:  2022-05-31       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.